• Navamedic ASA: Q3 2019 financial results

    Read more
  • News

    Navamedic’s prescription pharmaceutical for treatment of obesity draws Nordic media attention

    Read more
  • Business Development

    Read more
  • Presentations

    Read more

Portfolio

Our products

The portfolio includes generic, branded and patented pharmaceuticals as well as medical devices. The products are sold to hospitals, through pharmacies and directly to medical professionals.

The Consumer care product portfolio includes a variety of non-prescription drugs and health care products, mainly sold through pharmacies and drugstores. The portfolio includes both Navamedic owned and in-licensed brands. Future sales are secured through pharmacy chain agreements in the Nordic countries.

Medical nutrition

The Medical nutrition business segment is based on the sale of products for the treatment of inborn errors of metabolism (IEM). It includes the distribution agreement with the UK based Company Vitaflo International ltd for the Nordic region. Vitaflo International have over 30 years of experience in producing specialist nutritional product for inborn errors of metabolism (IEM). Please find below the product areas.

Navamedic ASA is a Norwegian medtech and pharmaceutical company, marketing products to hospitals and pharmacies in the Nordic and Benelux markets. The Group's Medtech business has developed and is currently introducing the next generation digital urine meter Sippi®
Navamedic Pharma and Healthcare business markets products supplied by a number of pharmaceutical manufacturers.
Navamedic is listed on the Oslo Stock Exchange (ticker: NAVA).

The Company operates in four business areas; Medical Devices, Pharma Products, Medical Nutrition and Consumer Care based on its relationship with a number of pharmaceutical product manufacturers.